Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Deerfield Partners
3870
Deerfield Partners
Suggest edits
Follow us
Also headquartered in San Francisco
Twitter
Uber
Instagram
Airbnb
Lyft
Fitbit
LinkedIn
TikTok
Salesforce
Reddit
Overview
News
Investments
3
Portfolio
Portfolio Tracker
Add info
Xconomy
,
MedCity News
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
MedCity News
bluebird bio's stock tanks after report of serious toxicity in sickle cell patient
$85,500,000
IPO
PE HUB
Xeris Pharmaceuticals goes public
Stock markets
$70,000,000
Post-IPO equity
PE HUB
Dicerna scores $70 mln
Funding
Stock markets
$250,000,000
Post-IPO equity
Twitter
Boston Business on Twitter
$41,000,000
Venture capital (Series C)
Xconomy
Austin Biotech Xeris Names Edick CEO, Raises $41M in Series C Round
Health
Funding
The Motley Fool
Better Buy: Agenus Inc. vs. bluebird bio
The Motley Fool
Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today
The Motley Fool
Better Buy: bluebird bio vs. Inovio Pharmaceuticals
The Motley Fool
Better Buy: Juno Therapeutics vs. bluebird bio
The Motley Fool
bluebird bio Inc: Catnapping in Cambridge
The Motley Fool
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
The Motley Fool
bluebird bio, Inc. Takes Flight Towards First Approval
The Motley Fool
Here's Why bluebird bio.'s Stock Tumbled in March
The Motley Fool
Why bluebird bio's Stock Jumped 12.9% on Wednesday
The Motley Fool
Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals
The Motley Fool
Why Bluebird Bio Inc. Plunged Today
The Motley Fool
Why bluebird bio Inc Presented a Lower Price Today
The Motley Fool
Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today
Stock markets
The Motley Fool
Why bluebird bio Inc.'s Stock Dropped 34% in January
Stock markets
